Vladimir Vexler - 04 Jan 2022 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: Chief Scientific Officer
Signature: /s/ McDavid Stilwell, as Attorney-in-Fact for Vladimir Vexler
Issuer symbol: CHRS
Transactions as of: 04 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2022, 18:48:53 UTC
Next filing: 12 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CHRS	Common Stock	Award	$0	+40,000	+53%	$0.000000	115,154	04 Jan 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+80,000		$0.000000	80,000	04 Jan 2022	Common Stock	80,000	$15.94	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2	Includes 112,083 RSUs.
F3	Includes 1,768 shares acquired on November 15, 2021, pursuant to Issuer's employee stock purchase plan.
F4	The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.